Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by University of Chicago.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT00203970
First received: September 12, 2005
Last updated: September 4, 2013
Last verified: August 2010

September 12, 2005
September 4, 2013
February 2001
March 2001   (final data collection date for primary outcome measure)
retrospective chart review to determine how patients with deep venous thromboses or pulmonary emboli were treated when hospitalized on the medicine services [ Time Frame: June 1997 to December 2000 ] [ Designated as safety issue: No ]
Using the data abstraction form, we gathered the following information: 1) patient demographics, 2) the identity of the attending, resident, and intern caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving LMWH, as delineated by the DVT critical pathway, including insurance status and 4) how the patient was treated for his/her condition.
Not Provided
Complete list of historical versions of study NCT00203970 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services

The purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. In particular, we are interested in how medical innovations diffuse throughout social networks. We wish to examine the diffusion of Low Molecular Weight Heparin (LMWH) use for Deep Vein Thrombosis (DVT) throughout the social network of general internal medicine interns, residents, and attendings at the University of Chicago Hospital. In numerous clinical trials, LMWH has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term anticoagulation therapy with Coumadin, with the added benefit of early discharge from the hospital with easy dosing, no need for monitoring, and home therapy. A DVT critical pathway was established at the U of C in 1998, and LMWH was used off-label for that purpose beginning in 1997. However, it is unclear how quickly the use of LMWH was adopted by the physicians on the general medicine services, or whether there exists a pattern for this adoption.

The design of our study is retrospective in nature. We are interested primarily in the use of LMWH in patients admitted to the general medicine services between January 1, 1997 and February 1, 2001 with a primary and secondary diagnosis related to Venous Thromboembolism, including specific ICD-9 codes.

Using a data abstraction form, we gather the following information: 1) patient demographics, 2) identity of the attending, resident, and interns caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving LMWH, as delineated by the DVT critical pathway, including insurance status and 4)how the patient was treated for his/her condition. To examine whether the identity of the primary care physician affects whether LMWH is given, we also collect the name of the primary care physician if it is listed on the chart.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients admitted into the general medicine services with a primary or secondary diagnosis related to Venous Thromboembolism.

Thrombosis
Behavioral: Observation
Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
645
January 2014
March 2001   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients admitted to General Medicine Services with a primary or secondary diagnosis related to venous thromboembolism

Exclusion Criteria:

  • Non-General Medicine Services patients
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00203970
10895A
No
University of Chicago
University of Chicago
Not Provided
Principal Investigator: David Meltzer, M.D., Ph.D. University of Chicago
University of Chicago
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP